



Dear Valued Client,

We are writing to inform you of an important change regarding **UTIDX® testing**.

After careful consideration, EmeritusDX and Freedom Pathology have made the difficult decision to discontinue our UTIDX® testing service effective **August 31st, 2026**

We want to emphasize that this decision **does not reflect a change in our belief in the clinical utility of UTIDX®**. We remain proud of the test, the clinical information it has provided, and the role it has played in helping physicians evaluate and manage patients with suspected urinary tract infections.

Unfortunately, the reimbursement environment for molecular UTI testing has become increasingly uncertain. Despite the clinical value we believe this testing provides, the continued unpredictability surrounding payer coverage, reimbursement, and retrospective payment adjustments makes it difficult to responsibly continue offering UTIDX®.

What this means for your practice

We will continue accepting UTIDX® specimens through **August 31st, 2026**. Our team will work closely with your practice to help ensure an orderly transition and address any questions regarding outstanding specimens or results.

Importantly, **this change is limited to UTIDX® testing**. EmeritusDX and Freedom Pathology remain fully committed to supporting your practice through our broader portfolio of diagnostic services, including molecular diagnostics, anatomic pathology, cytology, FISH, hematopathology, gastrointestinal testing, women's health, and other specialty testing services.

Our commitment to your practice—and to providing high-quality, clinically actionable diagnostic information—remains unchanged.

If you have questions regarding this transition or would like to discuss alternative testing options, please contact your EmeritusDX/Freedom Pathology representative.

Thank you for your continued partnership.

EmeritusDX and Freedom Pathology

Together, we save lives.